Wei-Lun Huang

Dr. Wei-Lun Huang

1. Center of Applied Nanomedicine, National Cheng Kung University, Tainan 701, Taiwan
+1

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
CSChun-Yan Shih
Chun-Yan Shih
PWPei-Ting Wang
Pei-Ting Wang
Wu-Chou  SuWu-Chou Su
Wu-Chou Su
HTHsisheng Teng
Hsisheng Teng
Wei-Lun HuangWei-Lun Huang
Wei-Lun Huang
Since the first clinical cancer treatment in 1978, photodynamic therapy (PDT) technologies have been largely improved and approved for clinical usage in various cancers. Due to the oxygen-dependent nature, the application of PDT is still limited by hypoxia in tumor tissues. Thus, the development of effective strategies for manipulating hypoxia and improving the effectiveness of PDT is one of the most important area in PDT field. Recently, emerging nanotechnology has benefitted progress in many areas, including PDT. In this review, after briefly introducing the mechanisms of PDT and hypoxia, as well as basic knowledge about nanomedicines, we will discuss the state of the art of nanomedicine-based approaches for assisting PDT for treating hypoxic tumors, mainly based on oxygen replenishing strategies and the oxygen dependency diminishing strategies. Among these strategies, we will emphasize emerging trends about the use of nanoscale metal–organic framework (nMOF) materials and the combination of PDT with immunotherapy. We further discuss future perspectives and challenges associated with these trends in both the aspects of mechanism and clinical translation.

26 April 2023 in Nanoscale
Verified
Journal Article
Closed access
PDF file
CSChun-Yan Shih
Chun-Yan Shih
PWPei-Ting Wang
Pei-Ting Wang
WCWei-Pang Chung
Wei-Pang Chung
WWWen-Hsiu Wang
Wen-Hsiu Wang
ICI-Ting Chiang
I-Ting Chiang
HTHsisheng Teng
Hsisheng Teng
Cancer cells tend to have higher intracellular reactive oxygen species (ROS) levels and are more vulnerable to ROS-generating therapies such as ascorbic acid (H2Asc) therapy, whose potency has been explored by several clinical trials. However, its efficiency is restricted by the requirement of pharmacologically high local H2Asc concentrations. Here, we show that nitrogen-doped graphene oxide dots (NGODs), which are highly crystalline and biocompatible, can serve as a catalytic medium for improving H2Asc cancer therapy at orally achievable physiological H2Asc concentrations. NGODs catalyze H2Asc oxidation for H2O2 and dehydroascorbic acid generation to disrupt cancer cells by consuming intracellular glutathione (GSH) and inducing ROS damage. This is the first study to demonstrate the direct consumption of GSH using a carbon-based nano-catalyst (NGODs), which further expedites tumor killing. In addition, as in our previous study, NGODs can also serve as a highly efficient photosensitizer for photodynamic therapy. Under illumination, NGODs produce a considerable amount of H2O2 in the presence of physiological levels of H2Asc as a hole scavenger and further enhance the therapeutic efficiency. Thus, a concise nanotherapeutic modality could be achieved through the conjunction of multifunctional NGODs and H2Asc to selectively eliminate deep-seated and superficial tumors simultaneously (under 65% of normal cell viability, it kills almost all cancer cells). Note that this level of therapeutic versatility generally requires multiple components and complex manufacturing processes that run into difficulties with FDA regulations and clinical applications. In this study, the concise NGOD–H2Asc nanotherapeutic modality has demonstrated its great potential in cancer therapy.

21 February 2026 in Advanced Healthcare Materials
Verified
Journal Article
Open access
PAPooja Aich
Pooja Aich
WCWei‐Pang Chung
Wei‐Pang Chung
WWWen‐Jyun Wang
Wen‐Jyun Wang
HTHidenobu Takahashi
Hidenobu Takahashi
MHMing‐Shun Hsieh
Ming‐Shun Hsieh
Wei-Lun HuangWei-Lun Huang
Wei-Lun Huang
The SARS‐CoV‐2 spike protein facilitates viral entry into host cells by binding to the human angiotensin‐converting enzyme 2 (ACE2) receptor. To exploit this mechanism for therapeutic intervention, a liposome fusion‐induced membrane exchange (LIME) strategy to generate biomimetic membrane‐integrated liposomes (MILs) from ACE2‐overexpressing mammalian cells was developed. Using engineered HeLa cells as a model, MILs have been successfully harvested that retained native surface proteins, including ACE2, as confirmed by immunogold TEM and Western blot analysis. These ACE2‐presenting MILs were then coated onto copper nanoparticles (Cu NPs), creating biomimetic Cu@MIL nanostructures with dual functions, including selective viral capture via ACE2‐mediated binding and neutralization, as well as potent antiviral activity from Cu NP disinfection. This synergistic platform effectively camouflages the nanomaterial with host‐mimetic membranes, conferring targeted viral neutralization and disinfection capabilities. Our findings highlight the potential of Cu@MIL nanoparticles as a decoy‐plus antiviral therapeutic for SARS‐CoV‐2, offering a promising strategy to combat COVID‐19 and future pandemics of receptor‐specific pathogens.

17 November 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
CCChi-Yi Chen
Chi-Yi Chen
CHChe-Yu Hsu
Che-Yu Hsu
WCWei-Pang Chung
Wei-Pang Chung
Hung-Yu SunHung-Yu Sun
Hung-Yu Sun
TKTzu-Ching Kao
Tzu-Ching Kao
KYKung-Chia Young
Kung-Chia Young
Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent worldwide and represents a growing healthcare challenge due to its risk of progression and association with metabolic comorbidities. Extracellular vesicles (EVs), nanosized membrane-bound particles mediating intercellular communication, have emerged as candidate biomarkers in multiple diseases. This study aimed to characterize serum EV profiles in MASLD patients, stratified into obese and lean groups using a body mass index cutoff of 23 for Asians. Methods: We enrolled 170 MASLD patients, 83 obese (median age 50, range 20–80) and 87 lean (median age 50, range 20–87), along with 57 non-MASLD controls (median age 44, range 21–86). Serum EV concentrations and particle sizes were quantified using nanoparticle tracking analysis and correlated with clinical and laboratory parameters. EV cargo proteins, including tetraspanins (CD9, CD63) and lipid droplet-associated perilipins (PLIN2, PLIN3), were assessed by Western blotting. Results: Obese MASLD patients displayed marked biochemical abnormalities, whereas lean MASLD patients showed levels comparable to non-MASLD controls. Nevertheless, serum EV concentrations were elevated in both the obese and lean MASLD groups. Importantly, in lean MASLD, EV levels correlated strongly with disruptions in lipid and glycemic homeostasis. Furthermore, a reduction in the PLIN3/CD63 ratio was observed in EVs isolated from lean MASLD patients. Conclusions: Circulating EVs are elevated in both obese and lean MASLD, but lean patients demonstrate a distinctive decrease in the EV PLIN3/CD63 ratio. These findings highlight the potential of EV profiling to uncover disease heterogeneity and to inform risk stratification in MASLD.

12 October 2026 in Bioprocess and Biosystems Engineering
Verified
Journal Article
Closed access
PDF file
TTTsung-Yu Tseng
Tsung-Yu Tseng
HTHsing-Fen Tsai
Hsing-Fen Tsai
YCYun Chen
Yun Chen
KHKeng-fu Hsu
Keng-fu Hsu
Wei-Lun HuangWei-Lun Huang
Wei-Lun Huang
Chao-Ling YaoChao-Ling Yao
Chao-Ling Yao